Expression of CD40 and growth-inhibitory activity of CD40 agonist in ovarian carcinoma cells

Cancer Immunology, Immunotherapy

Volumn 61, Issue 10, 2012, Pages 1735-1743

  Zhou, Yan ^a   He, Jing ^a   Gou, Lan Tu ^a   Mu, Bo ^a   Liao, Wei Chan ^a   Ma, Cong ^a   Tang, Ping ^a   Zhou, Shi Jie ^a   Zhou, Yong Jun ^a   Yang, Jin Liang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Agonist antibody; CD40; CD40L; Ovarian carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CD40 AGONIST MONOCLONAL ANTIBODY; CD40 ANTIGEN; CD40 LIGAND; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; RECOMBINANT SOLUBLE HUMAN CD40 LIGAND; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CELL ASSAY; CELL GROWTH; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; STAINING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD40; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; YOUNG ADULT;

EID: 84867571398     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1194-0     Document Type: Article

References (41)

1. Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK (2009) Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 15(8):2695-2702. doi:1078-0432.CCR-08-2966
2. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ (2009) Recurrent lowgrade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114(1):48-52. doi:S0090-8258(09)00139-5
3. Gerestein CG, Eijkemans MJ, de Jong D, van der Burg ME, Dykgraaf RH, Kooi GS, Baalbergen A, Burger CW, Ansink AC (2009) The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG 116(3):372-380. doi:10.1111/j.1471-0528.2008. 02033.x
4. Chiodoni C, Iezzi M, Guiducci C, Sangaletti S, Alessandrini I, Ratti C, Tiboni F, Musiani P, Granger DN, Colombo MP (2006) Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med 203(11):2441-2450. doi:jem.20060844
5. Maisch T, KropV B, Sinzger C, Mach M (2002) Upregulation of CD40 expression on endothelial cells infected with human cytomegalovirus. J Virol 76(24):12803-12812
6. Castigli E, Wilson SA, Elkhal A, Ozcan E, Garibyan L, Geha RS (2007) Transmembrane activator and calcium modulator and cyclophilin ligand interactor enhances CD40-driven plasma cell diVerentiation. J Allergy Clin Immunol 120(4):885-891. doi:10. 1016/j.jaci.2007.06.012
7. Luczynski W, Kowalczuk O, Ilendo E, Stasiak-Barmuta A, Krawczuk- Rybak M (2007) Upregulation of antigen-processing machinery components at mRNA level in acute lymphoblastic leukemia cells after CD40 stimulation. Ann Hematol 86(5):339-345. doi:10.1007/s00277-007-0256-z
8. Vanden Bush TJ, Bishop GA (2008) TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation. Eur J Immunol 38(2):400-409. doi:10.1002/eji.200737602
9. Burysek L, Syrovets T, Simmet T (2002) The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and janus kinase (JAK)/STAT signaling pathways. J Biol Chem 277(36):33509-33517. doi:10.1074/jbc.M201941200
10. Lefrancois L, Altman JD, Williams K, Olson S (2000) Soluble antigen and CD40 triggering are suYcient to induce primary and memory cytotoxic T cells. J Immunol 164(2):725-732. doi:ji-v164n2p725
11. Villarroel Dorrego M, Speight PM, Barrett AW (2007) CD40 in human oral epithelia. Oral Oncol 43(7):626-633. doi:S1368- 8375(06)00317-4
12. Lee JK, Seki N, Sayers TJ, Subleski J, Gruys EM, Murphy WJ, Wiltrout RH (2005) Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L. Cell Immunol 235(2):145-152. doi:10.1016/j.cellimm.2005.08.029
13. Bereznaya NM, Kirnasovskaya EA, Vinnichuk YD, Belova OB, Lukyanova NY (2008) Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. Exp Oncol 30(4):295-299
14. Jang TJ (2002) Expression of CD40 and Fas ligand in Bowen's disease, squamous cell carcinoma and basal cell carcinoma. Yonsei Med J 43(3):304-308
15. Wu JQ, Zhao WH, Yin KS, Cheng YL (2007) Adeno-Associated virus-mediated CD40 ligand transfer into human lung cancer cells. Zhonghua Zhong Liu Za Zhi 29(4):253-257
16. Zhou Z, Shi Q, Wang J, Pan J, Zhang X (2000) Anti-CD40 McAb induces CD40+ malignant B cell proliferation arrest and apoptosis. Zhonghua Xue Ye Xue Za Zhi 21(5):237-239. doi:10.1016/j. oraloncology.2006.12.008
17. Dzojic H, Loskog A, Totterman TH, Essand M (2006) Adenovirus- mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate 66(8):831-838. doi:10.1002/pros.20344
18. Villarroel Dorrego M, Whawell SA, Speight PM, Barrett AW (2006) Transfection of CD40 in a human oral squamous cell carcinoma keratinocyte line upregulates immune potency and costimulatory molecules. Br J Dermatol 154(2):231-238. doi:10.1111/j.1365-2133.2005.07006.x
19. Mayr C, KoXer DM, Buning H, Bund D, Hallek M, Wendtner CM (2005) Transduction of CLL cells by CD40 ligand enhances an antigen-speciWc immune recognition by autologous T cells. Blood 106(9):3223-3226
20. Morel Y, Truneh A, Sweet RW, Olive D, Costello RT (2001) The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit speciWc CTL activity. J Immunol 167(5):2479-2486
21. von Euler H, Sadeghi A, Carlsson B, Rivera P, Loskog A, Segall T, Korsgren O, Totterman TH (2008) EYcient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother 31(4):377-384. doi:10.1097/CJI. 0b013e31816a 812d
22. Zhou H, Xi H, Ma QR, Chen C, Zhang F, Zhang XG, Gu ZJ (2007) Therapeutic eVect of agonistic CD40 monoclonal antibody combined with CTL on hu-SCID mouse B lymphoma model. Zhonghua Zhong Liu Za Zhi 29(3):181-185
23. Wu Y, Wang L, He X, Xu H, Zhou L, Zhao F, Zhang Y (2008) Expression of CD40 and growth-inhibitory activity of CD40 ligand in colon cancer ex vivo. Cell Immunol 253(1-2):102-109. doi:S0008-8749(08)00103-2
24. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ (2009) Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229:152-172
25. Li R, Chen WC, Pang XQ, Zhang XG (2009) Expression of CD40 in human gastric cancer tissue and its prognostic correlation. Zhonghua Yi Xue Za Zhi 89(30):2124-2128
26. Bereznaya NM, Chekhun VF (2007) Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy. Exp Oncol 29(1):2-12
27. Posner MR, Cavacini LA, Upton MP, Tillman KC, Gornstein ER, Norris CM Jr. (1999) Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Clin Cancer Res 5(8):2261-2270
28. Melichar B, Patenia R, Gallardo S, Melicharova K, Hu W, Freedman RS (2007) Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines. Gynecol Oncol 104(3):707-713. doi:10.1016/j.ygyno. 2006.10.056
29. Hollmann A, Aloyz R, Baker K, Dirnhofer S, Owens T, Sladek R, Tzankov A (2010) Vav-1 expression correlates with NFkappaB activation and CD40-mediated cell death in diVuse large B-cell lymphoma cell lines. Hematol Oncol 28(3):142-150. doi:10.1002/hon.935
30. Fotin-Mleczek M, Henkler F, Hausser A, Glauner H, Samel D, Graness A, Scheurich P, Mauri D, Wajant H (2004) Tumor necrosis factor receptor-Associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-kappaB activation. J Biol Chem 279(1):677-685. doi:10.1074/jbc.M310969200
31. Bishop GA, Moore CR, Xie P, Stunz LL, Kraus ZJ (2007) TRAF proteins in CD40 signaling. Adv Exp Med Biol 597:131-151. doi:10.1007/978-0-387-70630-6-11
32. Jiang E, He X, Chen X, Sun G, Wu H, Wei Y, Zhao X (2008) Expression of CD40 in ovarian cancer and adenovirus-mediated CD40 ligand therapy on ovarian cancer in vitro. Tumori 94(3):356-361
33. Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS (2005) Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 65(18):8331-8338. doi:10.1158/0008-5472.CAN-05-0095
34. Kelley SK, Gelzleichter T, Xie D, Lee WP, Darbonne WC, Qureshi F, Kissler K, OXazoglu E, Grewal IS (2006) Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 148(8):1116-1123
35. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC (2004) Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 64(8):2846-2852
36. Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, Harrop K, Drachman JG, Whiting N (2010) A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 95(5):845-848. doi:10.3324/haematol.2009.008003
37. Ronald PG, Timothy P, Susan HC et al. (2011) The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor eYcacy in SCID-hu mice. Cancer Immunol Immunother. doi:10.1007/s00262-011-1014-6
38. Tutt AL, O'Brien L, Hussain A, Crowther GR, French RR, Glennie MJ (2002) T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 168(6):2720- 2728
39. Davis ID, Chen Q, Morris L et al (2006) Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells eYciently in cancer patients. J Immunother 29:499-511
40. French RR, Chan HT, Tutt AL, Glennie MJ (1999) CD40 antibody evokes a cytotoxic T cell response that eradicates lymphoma and bypasses T cell help. Nat Med 5:548-553
41. Mackey MF, Gunn JR, Ting PP et al (1997) Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res 57:2569-2574